Advertisement

BioDrugs

, Volume 33, Issue 6, pp 595–598 | Cite as

Acknowledgement to Referees

Acknowledgement to Referees
  • 163 Downloads

Dear Reader,

As we reach the final issue of BioDrugs for 2019, we wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content.

2019 was a successful year for BioDrugs. Over 60 articles have been published; the most popular of these, in terms of downloads from SpringerLink, have been:

  • Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. T. Virtanen, A., Haikarainen, T., Raivola, J. et al. BioDrugs (2019) 33: 15.  https://doi.org/10.1007/s40259-019-00333-w

  • Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. Springuel, L., Lonez, C., Alexandre, B. et al. BioDrugs (2019) 33: 515.  https://doi.org/10.1007/s40259-019-00368-z

  • Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter? George, K. & Woollett, G. BioDrugs (2019) 33: 447.  https://doi.org/10.1007/s40259-019-00374-1

  • Evolution of the EU Biosimilar Framework: Past and Future. Wolff-Holz, E., Tiitso, K., Vleminckx, C. et al. BioDrugs (2019).  https://doi.org/10.1007/s40259-019-00377-y

  • Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab. Hutterer, K.M., Polozova, A., Kuhns, S. et al. BioDrugs (2019) 33: 321.  https://doi.org/10.1007/s40259-019-00350-9

  • Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial. Suh, CH., Yoo, D.H., Berrocal Kasay, A. et al. BioDrugs (2019) 33: 79.  https://doi.org/10.1007/s40259-018-00331-4

  • An Efficient Development Paradigm for Biosimilars. Webster, C.J., Wong, A.C. & Woollett, G.R. BioDrugs (2019).  https://doi.org/10.1007/s40259-019-00371-4

  • Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. Busse, P.J., Farkas, H., Banerji, A. et al. BioDrugs (2019) 33: 33.  https://doi.org/10.1007/s40259-018-0325-y

  • Oncolytic Viruses: Priming Time for Cancer Immunotherapy. Russell, L., Peng, K.W., Russell, S.J. et al. BioDrugs (2019) 33: 485.  https://doi.org/10.1007/s40259-019-00367-0

  • Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals. Pawłowska, I., Pawłowski, L., Krzyżaniak, N. et al. BioDrugs (2019) 33: 183.  https://doi.org/10.1007/s40259-019-00341-w

Social media sharing of information has become important and is another metric with which to measure the reach of articles. This year the following articles published in BioDrugs scored highly on the Altmetric system:

  • Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter? George, K. & Woollett, G. BioDrugs (2019) 33: 447.  https://doi.org/10.1007/s40259-019-00374-1

  • Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies. Springuel, L., Lonez, C., Alexandre, B. et al. BioDrugs (2019) 33: 515.  https://doi.org/10.1007/s40259-019-00368-z

  • The Impact of the Fecal Microbiome on Cancer Immunotherapy. Osman, A.E.G. & Luke, J.J. BioDrugs (2019) 33: 1.  https://doi.org/10.1007/s40259-018-0328-8

  • Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis. Lee, S., Lee, H. & Kim, E. BioDrugs (2019) 33: 469.  https://doi.org/10.1007/s40259-019-00376-z

  • Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA). Hermosilla, J., Sánchez-Martín, R., Pérez-Robles, R. et al. BioDrugs (2019) 33: 193.  https://doi.org/10.1007/s40259-019-00342-9

The quality of articles published in the journal is also reflected in its most recent Journal Impact Factor of 4.903 (a 28% increase over the 2017 value). BioDrugs is now ranked 24/267 in the Pharmacology & Pharmacy journal category (91st percentile), and is also in the first quartile for the Oncology and Immunology categories. The Journal’s CiteScore (Scopus) is 4.74 (a 41% increase over 2017), with a ranking of 8/232 (96th percentile) in the Medicine—Pharmacology (Medicine) category.

We thank the authors who have contributed articles to BioDrugs over the course of 2019. The skill and dedication of all authors are critical to the continued publication of the journal. The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard. We would like to thank the following individuals who acted as reviewers for BioDrugs in the last 12 months:

Mario Acunzo, USA

Jeonghoon Ahn, Republic of Korea

Joachim Alexandre, France

Mehdi Arbabi-Ghahroudi, Canada

Nicolas Azzopardi, France

Kesavan Babu, USA

Rong Bai, China

Andrea Becciolini, Italy

Alain Beck, France

Charles L. Bennett, USA

Mikel Berdud, UK

Lokesh Bhatt, India

François Bocquet, France

Praveen K. Bommareddy, USA

Giulia Bonaldo, Italy

Ronald R. Bowsher, USA

Vitalis Briedis, Lithuania

Yves Briers, Belgium

Richard A. Brook, USA

Michael Brown, Australia

Nicola Brunetti Pierri, Italy

Chris Burns, UK

Michael Butler, Ireland

Myrna Candelaria, Mexico

Giancarlo Castaman, Italy

Ji-Yih Chen, Taiwan

Andrea Chiricozzi, Italy

Christos Chouaïd, France

Pratima Chowdary, UK

Hillel P. Cohen, USA

Pablo Conesa Zamora, Spain

Paul Cornes, UK

Tapan Das, USA

Ronilda D’Cunha, USA

Ilse Degreef, Belgium

Christopher DeRenzo, USA

Richard Dolinar, USA

George Dranitsaris, Canada

Erwin Dreesen, Belgium

Alexandros A. Drosos, Greece

Niklas Ekman, Finland

Alex Eustace, Ireland

Stefano Fais, Italy

Steven R. Feldman, USA

Simone Ferrero, Italy

Walter Fries, Italy

Justin F. Gainor, USA

Pilar Garcia, Spain

Pere Gascon, Spain

Salah Ghabri, France

David Gibson, Australia

David E. Gilham, Belgium

Roberto Giugliani, Brazil

Brian Godman, Sweden

Rui Gong, China

Jo Goodman, UK

Boris Gorovits, USA

Dennis Goulet, USA

Tomasz Grabowski, Poland

Maria Greenwald, USA

Sonia Guedan, Spain

László Gulácsi, Hungary

Scott Hart, USA

Jason E. Hawkes, USA

Yong-Seok Heo, Republic of Korea

Andrew Herr, USA

Kevin Hollevoet, Belgium

Seok H. Hong, USA

Imran G. House, Australia

Li-feng Hsu, Taiwan

Shi Hu, China

Jin A. Hwang, Republic of Korea

Ylenia Ingrasciotta, Italy

Melody Janssen, the Netherlands

Xu-Rong Jiang, USA

Zoltan Kalo, Hungary

Maria Kamusheva, Bulgaria

Patrick D.W. Kiely, UK

Janine Kimpel, Austria

Carol Kirchhoff, USA

Varun M. Kumar, USA

Pekka Kurki, Finland

Takashi Kuwabara, Japan

Carlos López-Morales, Mexico

Junyun Lai, Australia

Gilles Lambert, France

Howard Lee, Republic of Korea

Wei Li, USA

Michael N. Liebman, USA

Ruth R. Lopert, USA

Manoela Manova, Bulgaria

Maurie Markman, USA

Daniele Mengato, Italy

Tim Menzen, Germany

Andrea Messori, Italy

Linda Mileshkin, Australia

Adriana M. Montaño, USA

Daniel Montaner, Spain

Evelien Moorkens, Belgium

Heather Myler, USA

Eduardo E. Mysler, Argentina

Michael Naso, USA

Chee-Keng Ng, USA

Shingo Niimi, Japan

Jesper Nordenskjöld, Sweden

Valentina Orlando, Italy

Christopher Ott, USA

Javin Oza, USA

Martin Pacesa, Switzerland

John Pakulski, USA

Ramesh Palaparthy, USA

Vidhya Parameswaran, Canada

Michael Partridge, USA

Luca Pasina, Italy

Susan Pederson, USA

Guenka I. Petrova, Bulgaria

Avery D. Posey, Jr, USA

Henrike Potthast, Germany

Steven Powell, USA

Frederick J. Raal, South Africa

Fatemeh Rahbarizadeh, Islamic Republic of Iran

Anurag S. Rathore, India

Joannes A. A. Reijers, the Netherlands

Paul Rhyne, USA

Robert M. Rifkin, USA

Carlos Sao-Jose, Portugal

Andrea Sartore-Bianchi, Italy

Morton Scheinberg, Brazil

Huub Schellekens, the Netherlands

Marcus Schmitt-Egenolf, Sweden

Christian K. Schneider, Denmark

Michael Seaman, USA

Suzanne M. Sensabaugh, USA

Umender Sharma, India

John Snowden, UK

Laura Soucek, Spain

Bruce S. Spinowitz, USA

Robert Stoekenbroek, USA

Chang-Hee Suh, Republic of Korea

Keith M. Sullivan, USA

Tomas Tesar, Slovakia

Robin Thorpe, UK

Anna Tinker, Canada

Shunji Tomatsu, USA

Zahi Touma, Canada

Susumu Uchiyama, Japan

Andrew Upsall, UK

Paul van Bergen en Henegouwen, the Netherlands

Femke van Rhijn-Brouwer, the Netherlands

Florence Velge-Roussel, France

Lise Verhoef, the Netherlands

Sarah Vreugde, Australia

Alessandra Vultaggio, Italy

Arnold G. Vulto, the Netherlands

Yongzhong Wang, China

Mark G. Ward, Australia

Norihiro Watanabe, USA

Martina Weise, Germany

Michelle K. Wilson, New Zealand

Elena Wolff-Holz, Germany

Gary Wong, China

Ye Xiong, USA

Jensen Yeung, Canada

Dae H. Yoo, Republic of Korea

Elisa Zanier, Italy

Zeineb Zian, Morocco

In addition, we would like to thank the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

L. Bergmann, Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany

E. De Clercq, Rega Instituut, Leuven, Belgium

G.D. Demetri, Dana Farber Cancer Institute, Boston, MA, USA

T.R. Flotte, University of Massachusetts Medical School, Worcester, MA, USA

T.M. Ganey, Vivex Biomedical, Atlanta, GA, USA

A. Ganser, Hannover Medical School, Hannover, Germany

H-P. Gerber, 3T Biosciences, Palo Alto, CA, USA

T.J. Giezen, Foundation Pharmacy for Hospitals in Haarlem, Haarlem, the Netherlands

B. Groner, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany

F. Guilhot, Université de Poitiers, Poitiers, France

W.H. Hildebrand, University of Oklahoma, Oklahoma City, OK, USA

P. Moingeon, Stallergenes, Paris, France

D. Müller, Universitat Stuttgart, Stuttgart, Germany

J.L. Murray, University of Texas MD Anderson Cancer Center, Houston, TX, USA

W. Park, Inha University Medical School, Incheon, Republic of Korea

C. Picado, Hospital Clinic de Barcelona, Barcelona, Spain

T. Schirrmann, YUMAB GmbH, Braunschweig, Germany

S. Sharfstein, SUNY Polytechnic Institute, Albany, NY, USA

C.A. Stein, City of Hope Medical Center, Duarte, CA, USA

R.C. Stevens, University of Southern California, Los Angeles, CA, USA

W.R. Strohl, BiStro Biotech Consulting, Bridgewater, NJ, USA

B.A. Sullenger, Duke University Medical Center, Durham, NC, USA

J. Terrett, Crispr Therapeutics, Inc., Cambridge, MA, USA

G. Trifirò, University of Messina, Sicily, Italy

P. Trzonkowski, Medical University of Gdansk, Gdansk, Poland

J.W. Van der Meer, University Medical Center St Radboud, Nijmegen, the Netherlands

G. Woollett, Avalere Health, Washington, DC, USA

We do hope that you have found the articles published throughout the year in BioDrugs to be interesting and informative. The editorial schedule for 2020 is well under way, and we are looking forward to bringing you many high-quality and authoritative articles over the coming year.

With best wishes

Kathy Fraser

Editor

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations